Navigation Links
Adheron Therapeutics Names New Senior Leadership
Date:9/11/2013

SAN FRANCISCO, Sept. 11, 2013 /PRNewswire/ -- Adheron Therapeutics, a biotechnology company that is focused on leveraging pioneering technology that disrupts cell adhesion to treat a variety of diseases, has announced the appointments of Robert Baltera as executive chairman of the board and Hari Kumar as chief executive officer, effective immediately.

Baltera and Kumar served most recently as senior officers of Amira Pharmaceuticals, which was acquired by Bristol Myers Squibb for $325M upfront and $150M in milestones. At Adheron Therapeutics - previously known as Synovex Corporation – Baltera and Kumar's focus will be developing the company's novel Cadherin-11 technology for various therapeutic indications.

"I am very excited about my new role at Adheron Therapeutics. I am deeply impressed by the innovative technology that we are developing and I look forward to advancing it to the next level," said Kumar.

The company's therapeutic program is based on pioneering work completed in the laboratory of Michael Brenner, MD, at Brigham and Women's Hospital and Harvard Medical School. Prof. Brenner discovered that the protein Cadherin-11 (Cad-11) acts as an "adhesive" between cells, and that changes in Cad-11 interactions can induce cells to produce proteins that influence the cellular environment positively or adversely. Further research by Dr. Brenner confirmed that Cad-11 acts as a key mediator of joint destruction in rheumatoid arthritis, and is also an important contributor to pulmonary and skin fibrosis pathology. 

Baltera added: "Cadherin-11 is a very promising technology, which I am confident will be applied in various areas of high unmet medical need. I am pleased to lead Adheron and I am confident we will see exciting results."

Based on Dr. Brenner's research, Adheron Therapeutics has developed an antibody that inhibits Cad-11. The company, which Dr. Brenner and Dr. David Lee established in 2006 as Synovex Corporation, plans to evaluate the benefits of this antibody in multiple therapeutic areas including cancer, rheumatoid arthritis and fibrosis, and advance it through clinical proof of concept. Adheron has just completed a Phase I single ascending-dose study for its lead asset, the Cad-11 inhibitor SDP051. 

Adheron Therapeutics is funded by Health Care Ventures, MedImmune Ventures, Partners Innovation Fund, Amgen Ventures, and SROne.

About CAD 11
Cadherin-11 (Cad-11) is a surface protein expressed on fibroblasts in the skin and lungs, and fibroblast-like synoviocytes (FLS) in the joints. Cad-11 acts as an "adhesive" between cells, and changes in Cad-11 interactions can induce the cells to produce proteins that influence the cellular environment positively or adversely. Research completed in the laboratory of Michael Brenner, MD, at Brigham and Women's Hospital and Harvard Medical School has implicated Cad-11 in the disease processes leading to rheumatoid arthritis. Work initiated in Dr. Brenner's laboratory by Dr. Sandeep Agarwal, now at Baylor College of Medicine, has also demonstrated that Cad-11 plays a role in diverse fibrotic diseases.

About Adheron Therapeutics
Adheron Therapeutics is a biotechnology company focused on leveraging pioneering technology that disrupts cell adhesion to treat a variety of diseases. Founded by Dr. Brenner and Dr. Lee of Harvard Medical School, the company is led by industry veterans Bob Baltera (executive chairman) and Hari Kumar, PhD (CEO), and funded by a group of venture investors comprising Health Care Ventures, MedImmune Ventures, Partners Investment Fund, Amgen Ventures, and SROne.

www.adherontherapeutics.com

Contact:
Jacqueline Wallach
650 283 6617
jacqueline.wallach@gilitycomms.com

Michele Parisi
925 429 1850
mparisi@biocommnetwork.com


'/>"/>
SOURCE Adheron Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Case Report Suggests Microbiome Therapeutics NM504 May Improve Tolerability of Metformin While Improving Blood Glucose Control
2. Echo Therapeutics Sends Response to Shareholder Letter
3. Convoy Therapeutics to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
4. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
5. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
6. AML Therapeutics Market in the 6MM Worth $430.7m in 2017 Says a New Research Report Available at ReportsnReports.com
7. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
8. Oncology Therapeutics Market in India to 2018 Report
9. PTC Therapeutics Announces Achievement Of Major Milestone In SMA Collaboration
10. NuMe Health Becomes MicroBiome Therapeutics And Recruits New CEO
11. Enteris BioPharma Initiates Business and Development Activities Targeting Oral Delivery of Peptides and Small Molecule Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 Eutilex Co. Ltd. today announced that ... Series A financing. This financing round included participation from ... SNU Bio Angel. This new funding brings the total ... $27.7M) since its founding in 2015. ... and commercialization of its immuno-oncology programs, expand its R&D ...
(Date:12/7/2016)... ... December 07, 2016 , ... A new ... the setting of previously treated, advanced pancreatic cancer, liquid biopsies are not yet ... population and timing of blood sampling may improve the value of a blood-based ...
(Date:12/7/2016)... CALGARY , Dec. 7, 2016 /PRNewswire/ - Zenith Capital Corp. ... update that will be presented at the Company,s Annual and ... Meeting of Shareholders will take place on Thursday, December 15, ... Ross Glenn Hall (Room EC1040), 4825 Mount Royal Gate ... am (MST). A notice of meeting and management information circular, ...
(Date:12/7/2016)... 7, 2016  Vyriad Inc. announced today the appointment ... Board of Directors. "We are delighted to ... business and develop our oncolytic viruses as the next ... Stephen Russell , MD, PhD, CEO of Vyriad. "Al ... vision and passion for making a difference for cancer ...
Breaking Biology Technology:
(Date:12/5/2016)...  The Office of Justice Programs, National Institute ... Enhance or Replace Medico Legal Autopsies?" on NIJ.gov.  ... replacing forensic autopsies with postmortem X-ray computed tomography, ... response to recommendations made by The National Academy ... as a potential component of medicolegal death investigations. ...
(Date:11/30/2016)... 30, 2016 Not many of us realize that we spend ? of ... we need to do it well. Inadequate sleep levels have been found to lead ... diabetes, and even cancer. Maybe now is the best time to rethink ... them to manage their sleep quality? Continue Reading ... ...
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
Breaking Biology News(10 mins):